The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1...
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1...
歐洲藥品管理局的醫藥產品人用委員會已採納了積極意見，推薦擴大再生元製藥公司/賽諾菲安萬特的杜派真（杜派魯瑪）在兒童中治療嗜酸性食管炎的適應症，年齡降低到1歲
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1 Year Of Age
歐洲藥品管理局的醫藥產品評估委員會通過了一個積極的意見，推薦擴大再生元製藥公司/賽諾菲安萬特的Dupixent（Dupilumab）用於兒童嗜酸性食管炎的批准年齡至1歲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。